Physician profile
Darren E Meyer
NPI 1467460204
$5,282.21
in general payments reported to CMS, 2019-2025
21 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $338 · 2021: $802 · 2022: $538 · 2023: $884 · 2024: $820 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318 · Education: $7.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,318.31 |
| Education | $7.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,304.57 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $854.13 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $760.13 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $581.62 | 2019-2022 | |
| Lundbeck LLC | $495.85 | 2019-2025 | Rexulti |
| Allergan, INC. | $198.61 | 2019 | |
| Merck Sharp & Dohme LLC | $172.65 | 2019-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $145.93 | 2019-2020 | |
| Alkermes, INC. | $127.62 | 2022-2023 | Lybalvi, Aristada |
| Shire North American Group INC | $122.98 | 2019 | |
| Validus Pharmaceuticals LLC | $106.53 | 2019-2024 | Equetro |
| Janssen Pharmaceuticals, INC | $75.88 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $74.53 | 2023-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $72.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.43 | 2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $34.11 | 2019 | |
| Orexo US, INC. | $32.74 | 2019 | |
| Adlon Therapeutics L.P. | $18.37 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.76 | 2019 | |
| Neos Therapeutics, Lp | $15.68 | 2020 | |
| Bausch Health US, LLC | $14.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.